Impact of the recent randomized trials on the use of progesterone to prevent preterm birth: A 2005 follow-up survey

被引:32
作者
Ness, Amen [1 ]
Dias, Todd
Damus, Karla
Burd, Irina
Berghella, Vincenzo
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Div Maternal Fetal Med, Dept Obstet & Gynecol, Philadelphia, PA 19107 USA
[2] March Dimes Perinatal Data Ctr, White Plains, NY USA
[3] Albert Einstein Coll Med, Dept Obstet & Gynecol, Bronx, NY 10467 USA
关键词
progesterone; 17 alpha-hydroxyprogesterone caproate; prevention of preterm birth; preterm birth;
D O I
10.1016/j.ajog.2006.06.034
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The purpose of this study was to determine whether current attitudes regarding the use of progesterone to prevent preterm birth have changed since our last survey in 2003. Study design: We mailed a 20 question survey to 1264 board certified Maternal-Fetal Medicine specialists in the United States between February and March of 2005 asking about their use and attitudes regarding progesterone to prevent preterm birth. Results: Five hundred and seventy-two surveys were returned (response rate of 45%). In 2005, 67% of respondents used progesterone to prevent SPTB, compared to 38% in 2003 (P < .001). Among users, 38% recommended progesterone for indications other than previous SPTB. Users were more concerned about lack of insurance coverage compared to nonusers but nonusers were more concerned about safety, efficacy, need for more data, and long-term neonatal effects. Conclusion: Although the use of progesterone to prevent PTB has increased significantly since our last survey, there remain a substantial number of nonusers. Among users, many are using it for indications not yet proven in clinical trials. Current nonusers have higher levels of concerns compared to nonusers in the first survey and their major concern is the need for more data. (c) 2006 Mosby, Inc. All rights reserved.
引用
收藏
页码:1174 / 1179
页数:6
相关论文
共 17 条
[1]  
American College of Obstetricians and Gynecologists, 2003, Obstet Gynecol, V102, P1115
[2]   Nongenital malformations following exposure to progestational drugs: The last chapter of an erroneous allegation [J].
Brent, RL .
BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2005, 73 (11) :906-918
[3]  
CHEZ RA, 1978, FERTIL STERIL, V30, P16
[4]   Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind study [J].
da Fonseca, EB ;
Bittar, RE ;
Carvalho, MHB ;
Zugaib, M .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 188 (02) :419-424
[5]   Prenatal administration of progesterone for preventing preterm birth [J].
Dodd, JM ;
Flenady, V ;
Cincotta, R ;
Crowther, CA .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (01)
[6]   Underuse of evidence-based therapies [J].
Hlatky, MA .
CIRCULATION, 2004, 110 (06) :644-645
[7]   Supplemental progesterone to prevent preterm birth [J].
Jams, JD .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 188 (02) :303-303
[8]   PROGESTOGEN ADMINISTRATION IN PREGNANCY MAY PREVENT PRETERM DELIVERY [J].
KEIRSE, MJNC .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1990, 97 (02) :149-154
[9]   Progesterone and preterm:: Seventy years of "deja vu" or "still to be seen"? [J].
Keirse, MJNC .
BIRTH-ISSUES IN PERINATAL CARE, 2004, 31 (03) :230-235
[10]  
MARTIN JA, 2005, PRELIMINARY BIRTHS 2